Prometheus Biosciences Inc Stock News

Nuveen Asset Management LLC bought a new position in shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX) in the second quarter, Holdings Channel reports. The firm bought 32,373 shares of the biopharmaceutical companys stock, valued at approximately $795,000. Other large investors have also recently modified their holdings of the company. Deutsche Bank AG purchased a new stake []

Charles Schwab Investment Management Inc. purchased a new position in shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 75,128 shares of the biopharmaceutical companys stock, valued at approximately $1,846,000. Charles Schwab Investment Management Inc. owned about []

Prometheus Biosciences Inc (RXDX) shares closed this week 21.3% lower than it did at the end of last week. The stock is currently up 19.8% year-to-date, up 19.8% over the past 12 months, and up 19.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 0.1%. Trading Activity Shares traded as high as $39.98 and as low as $26.99 this week.Trading volume this week was 29.7% lower than the 10-day average and 29.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -228.1% The company's stock price performance over the past 12 months beats the peer average by -188.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Prometheus Biosciences (NASDAQ: RXDX) recently received a number of ratings updates from brokerages and research firms: 11/18/2021 Prometheus Biosciences was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, Prometheus Biosciences Inc. is a biotechnology company. It involved in the discovery, development, and commercialization of []

Sanofi (NASDAQ:SNY) and Prometheus Biosciences (NASDAQ:RXDX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation. Institutional and Insider Ownership 8.0% of Sanofi shares are owned by institutional investors. Comparatively, 61.2% of Prometheus []

Shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX) hit a new 52-week high on Wednesday . The stock traded as high as $39.28 and last traded at $38.34, with a volume of 198842 shares traded. The stock had previously closed at $36.58. Several research analysts recently weighed in on the company. Oppenheimer downgraded Prometheus Biosciences from an []

Prometheus Biosciences (NASDAQ:RXDX) was downgraded by Oppenheimer from an outperform rating to a market perform rating in a research report issued to clients and investors on Monday, Price Targets.com reports. They currently have a $35.00 price objective on the biopharmaceutical companys stock. Oppenheimers price target points to a potential downside of 4.32% from the companys []

JPMorgan Chase & Co. acquired a new stake in Prometheus Biosciences, Inc. (NASDAQ:RXDX) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 6,822 shares of the biopharmaceutical companys stock, valued at approximately $168,000. Several other institutional investors also recently bought and sold shares of []

Prometheus Biosciences (NASDAQ:RXDX) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, missing the Zacks consensus estimate of ($0.59) by ($0.11), MarketWatch Earnings reports. RXDX traded down $0.68 during midday trading on Friday, reaching $36.32. 337,366 shares of the companys stock were exchanged, compared to []

Prometheus Biosciences (NASDAQ:RXDX) released its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts consensus estimates of ($0.59) by ($0.11), MarketWatch Earnings reports. Shares of RXDX opened at $36.32 on Friday. Prometheus Biosciences has a fifty-two week low of $16.11 and a fifty-two week high []

Prometheus Biosciences (NASDAQ:RXDX) and Sanofi (NASDAQ:SNY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Institutional & Insider Ownership 61.2% of Prometheus Biosciences shares are held by institutional investors. Comparatively, 8.0% of []

One way to find potential winning stocks is to search for companies that recently landed new analyst coverage.

SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, M.D., Chief Medical O

The shares of Prometheus Biosciences Inc (NASDAQ: RXDX) have received a $35 price target by Oppenheimer. These are the details.

Prometheus Biosciences: Precision Medicine For IBD